ClinicalTrials.Veeva

Menu

Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury

M.D. Anderson Cancer Center logo

M.D. Anderson Cancer Center

Status and phase

Withdrawn
Phase 2

Conditions

Hypertension
Proteinuria
Drug-Induced Nephropathy

Treatments

Drug: Placebo
Dietary Supplement: Arginine

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT02882373
P30CA016672 (U.S. NIH Grant/Contract)
NCI-2018-02537 (Registry Identifier)
2015-1105 (Other Identifier)

Details and patient eligibility

About

This phase II trial studies how well arginine works in treating patients with kidney injury caused by anti-VEGF drugs used in standard treatment for cancer. Arginine is a nutritional supplement that may control side effects of anti-cancer drugs such as high blood pressure and protein in the urine and may also help to improve kidney function in patients.

Full description

PRIMARY OBJECTIVES:

I. To assess the value and/or limitations of using orally supplemented arginine (L-arginine) to improve renal function associated with the use of anti-angiogenic therapies that target vascular endothelial growth factor (VEGF).

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive arginine orally (PO) four times daily (QID). Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.

GROUP II: Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment patients are followed up within 1 month.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • On or enrolled for anti-VEGF therapy
  • Systolic Blood Pressure >= 140 mm Hg
  • Diastolic Blood Pressure >= 90 mm Hg
  • Proteinuria >= 500 mg/day or worsening glomerular filtration rate (GFR) (> 0.3 mg/dl in 48 hours [hrs.] or > 50% decline from baseline creatinine in 1 week)

Exclusion criteria

  • Allergy to L-arginine
  • Systolic Blood Pressure < 140 mm Hg
  • Diastolic Blood Pressure < 90 mm Hg
  • Proteinuria < 500 mg/day
  • Continuous tube feeds (since the medication will be given in-between meals)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

0 participants in 2 patient groups, including a placebo group

Group I (arginine)
Experimental group
Description:
Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Dietary Supplement: Arginine
Group II (placebo)
Placebo Comparator group
Description:
Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems